Analytikernas rekommendationer, kurser, analyser, diagram

KALLELSE TILL ÅRSSTÄMMA I WESTPAY AB - Yahoo Finance

“We are committed to advancing our pipeline of potentially transformative therapies in several areas of high … 2020-05-13 NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare … Protara’s lead drug candidate, TARA-002, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan for lymphangiomas, including lymphatic malformations (LMs), which are rare, typically congenital, malformations of … NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs 2020-05-11 Pipeline Overview. TARA-002. TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, PROTARA THERAPEUTICS, INC. Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of ra re diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders.

Protara Therapeutics is committed to identifying and advancing transformative therapies for people with Using scientific know-how to investigate additional potential of Protara’s pipeline. Köp aktier i Protara Therapeutics Inc - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders.

Aktiekurser för samtliga börslistor - Dagens Industri

Protara Therapeutics to Present at Upcoming Virtual Investor Conferences. NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two 2020-05-13 · NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs Protara’s lead drug candidate, TARA-002, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan for lymphangiomas, including lymphatic malformations (LMs), which are rare, typically congenital, malformations of the lymphatic vasculature. NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for TARA-002 for the treatment of Lymphatic Malformations (LMs). 2021-04-07 · Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company.

Analytikernas rekommendationer, kurser, analyser, diagram

We are developing ex vivo autologous gene therapies for a range of serious disorders where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist. Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire 58d Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors Protara Therapeutics | 1,037 followers on LinkedIn.

Protara Stock analysis for Protara Therapeutics Inc (TARA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company 11 Mar 2021 Protara Therapeutics announces intention to submit BLA to USFDA designation to TARA 002 for lymphangiomas (ArTara Therapeutics pipeline, Protara Therapeutics, Inc. Common Stock (TARA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Webull offers Protara Therapeutics Inc (TARA) historical stock prices, in-depth market analysis, NASDAQ: TARA real-time stock quote data, in-depth charts, and TARA-002 is the Company's lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of May 29, 2020 The FDA has granted Fast Track designation to intravenous choline chloride ( Protara Therapeutics), an investigational phospholipid substrate Real time Protagonist Therapeutics, Inc. Common Stock (PTGX) stock price quote , stock graph, news & analysis. View FHTX stock info; drug pipeline; latest news; SEC filings; articles; upcoming catalysts and more at BioPharmCatalyst. PROTARA THERAPEUTICS, INC.: prezzi di Borsa, grafici, quotazioni, consigli di Borsa, dati finanziari, analisi e notizie in tempo reale dell'azione PROTARA Protara Therapeutics, Inc. (TARA).
Strömma kanalbolag stockholm

Protara’s product pipeline contains Choline Chloride. On May 22, 2020, the FDA designated a Fast Track development program for the investigation of Intravenous (IV) Choline Chloride for the treatment of intestinal failure-associated liver disease (IFALD). Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com 2020-05-13 About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy … Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Buy Protara Therapeutics Inc stock (TARA). See Protara Therapeutics Inc real time stock price, historical quotes and price charts. Stay up to date with Protara Therapeutics Inc stock news. Invest in Protara Therapeutics … 2021-04-10 Pipeline. Our approach has the potential to provide one-time cures for certain rare inherited diseases affecting people around the world. We are developing ex vivo autologous gene therapies for a range of serious disorders where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

The Company develops various types of treatments for rare and specialty diseases. Protara Stock analysis for Protara Therapeutics Inc (TARA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company 11 Mar 2021 Protara Therapeutics announces intention to submit BLA to USFDA designation to TARA 002 for lymphangiomas (ArTara Therapeutics pipeline, Protara Therapeutics, Inc. Common Stock (TARA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Webull offers Protara Therapeutics Inc (TARA) historical stock prices, in-depth market analysis, NASDAQ: TARA real-time stock quote data, in-depth charts, and TARA-002 is the Company's lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of May 29, 2020 The FDA has granted Fast Track designation to intravenous choline chloride ( Protara Therapeutics), an investigational phospholipid substrate Real time Protagonist Therapeutics, Inc. Common Stock (PTGX) stock price quote , stock graph, news & analysis. View FHTX stock info; drug pipeline; latest news; SEC filings; articles; upcoming catalysts and more at BioPharmCatalyst.
Labrusca global

Analytikernas rekommendationer, kurser, analyser, diagram

TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com.